News
The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old. Previously approved ...
A single booster shot of MenQuadfi can be given to people ages 13 years or older who are at a continued risk of IMD if it’s been at least three years since their last meningococcal vaccine.
Sanofi (SNY)'s share was trading at $51.06 ... by deep public-sector distribution—generated €2.25 billion, and MenQuadfi, a meningitis vaccine, posted 50.5% growth. Despite some expected ...
Meningitis remains a significant health problem, affecting 2.5 million people annually and causing death and disability despite the availability of vaccines such as Sanofi’s MenQuadfi that ...
May 27 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said ... The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against ...
Hosted on MSN14d
Sanofi (SNY)’s MenQuadfi Becomes First MenACWY Vaccine Approved for Ages 6 Weeks and UpT he U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old.Previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results